A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab REGN2810 for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Non-Matched Sub-Study

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT06616584

Study #:
STUDY00161469

Start Date:
May 30, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06616584

View Complete Trial Details & Eligibility at ClinicalTrials.gov